Federal award (DEFINITIVE CONTRACT, fiscal year 2023)
Recipient: BIOCRYST PHARMACEUTICALS INC
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2020-09-01 to 2022-09-30
Current total value of award: $2614651.55
Description: TO DE-OBLIGATE REMAINING FUNDS AND ADMINISTRATIVELY CLOSE THE CONTRACT.